DNA Self-Activating Warheads (SAWs)

Expanding the therapeutic index of antibody-drug conjugates



Blavatnik Full Award

Seth Herzon, PhD

2024–2025

ADC companies raised >$3B since 2022

Despite >$3B investment since 1/2022, ADCs do not consistently exceed the MTD of conventional chemotherapies



Identical trends observed for maytansinoid and PBD ADCs: *Cancer Discov.* **2024**, DOI: 10.1158/2159-8290.Cd-24-0708

Existing payloads are complex, difficult to manipulate, and pan-cytotoxic



Besponsa, B-cell precursor acute lymphoblastic leukaemia



Kadcyla, HER2-positive breast cancer



Enhertu, HER2-positive breast and gastric cancer

ChemMedChem **2022**, *17*, e202200032

SawCo Objective: Develop ADCs with expanded therapeutic index

Seth Herzon, PhD

- Milton Harris ‘29 PhD Professor of Chemistry, Yale University
- Professor of Pharmacology and Therapeutic Radiology, Yale School of Medicine.
- Co-Founder, Modifi Biosciences (oncology)

ModifiBio

Ranjit Bindra, MD, PhD

- Serial Entrepreneur, Radiation Oncologist
- Harvey and Kate Cushing Professor, Yale
- Co-Founder, Modifi Biosciences (oncology)

ModifiBio CYBREXA THERAPEUTICS Alphina

Alan R. Healy, PhD

- Assistant Professor of Chemistry, NYU
- Formerly Charles Revson Fellow, Chemistry and Chemical Biology Institute, Yale University

NYU

Robert Williams, PhD

- Blavatnik Fellow, Yale Ventures
- Biotech Startup Operator

YALE VENTURES PELAGOS PHARMACEUTICALS THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History® aumenta biosciences 7 HILLS PHARMA

SawCo is designing bespoke payloads for ADCs.



SAW modularity enables development of a pipeline of payloads with controllable physical properties and mechanisms of action.



Phys. props readily optimized

DNA binding affinity

Polarity, drug-like properties

Permeability

Controllable MOAs:
Pair with tumor-associated DNA repair defects

DNA monoalkylation agents

DNA cleavage agents (DSBs)

Cross-linking agents (ICLs)

Blavatnik + External Funding Strategy

De-risking the platform and bolstering IP position with Blavatnik Funding



Have optionality to develop novel ADCs, partner with a larger company, and/or develop payload platform to out license.